| Acquired by | Eli Lilly |
| Date | 7/10 |
| Website | alnara.com |
| Category | BioTech |
| Phone | 617-349-3690 |
| info@alnara.com | |
| Employees | |
| Founded | 2008 |
| Description | Healthcare Biotechnology |
| TOTAL | $55M |
| FUNDING TOTAL | $55M |
| Series A, 10/08 Bessemer Venture Partners Third Rock Ventures Frazier Healthcare Ventures | $20M |
| Series B, 1/10 MPM Capital | $35M |
Alnara Pharmaceuticals, Inc. is dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream.